(Stroke. 2000;31:1628.)
© 2000 American Heart Association, Inc.
Original Contributions |
From the Departments of Medicine (A.P.R, B.M.P., D.S.S.), Epidemiology (S.M.S, W.T.L., B.M.P., D.S.S.), Neurology (W.T.L.), and Cardiovascular Health Research Unit (A.P.R., S.M.S, R.M.P., B.M.P., D.S.S.), University of Washington, Seattle; Department of Pathology, PSG Institute of Medical Sciences and Research, Tamilnadu, India (P.N.K.); Fred Hutchinson Cancer Research Center, Seattle, Wash (S.M.S); and the Hemostasis and Thrombosis Research Center and Department of Clinical Epidemiology, University Hospital Leiden (Netherlands) (F.R.R.).
Correspondence to Alexander P. Reiner, MD, University of Washington, Box 359756, Seattle, WA 98195-9756. E-mail apreiner{at}u.washington.edu
| Abstract |
|---|
|
|
|---|
MethodsWe performed genotype analysis for 5 common diallelic platelet glycoprotein polymorphisms in a population-based study of 78 white women aged <45 years with arterial stroke (36 ischemic cases and 42 hemorrhagic cases) and 346 demographically similar control subjects.
ResultsThe 807T variant of glycoprotein Ia was
associated with a 2-fold increased risk of ischemic stroke
(age-adjusted odds ratio [OR]=2.24; 95% CI=0.99 to 5.06). The
Met145 allele of glycoprotein Ib
was
associated with a trend toward an increased risk of ischemic
stroke that was more pronounced in the homozygous state (OR=10.36), but
the CI is extremely wide because of the small numbers of subjects (95%
CI=1.43 to 79.34). Homozygosity for the Ser843 allele
of the glycoprotein IIb was associated with an
5-fold
increased risk of ischemic stroke among subgroups of women who
carried a diagnosis of hypertension or diabetes (OR=4.51; 95% CI=1.01
to 20.13) or had elevated plasma homocysteine levels (OR=5.94; 95%
CI=1.53 to 23.05). The genotype distributions for all 5
platelet glycoprotein polymorphisms were similar
among hemorrhagic stroke cases and controls.
ConclusionsSeveral inherited platelet glycoprotein variants may be associated with an increased risk of ischemic stroke in young women. These associations seemed to be confined to women with other cardiovascular risk factors. Additional studies involving larger numbers of subjects are needed to confirm these preliminary findings.
Key Words: platelets polymorphism stroke, hemorrhagic stroke, ischemic
| Introduction |
|---|
|
|
|---|
have been associated with
ischemic stroke in some studies, but not in
others.2 3 4 5 6 7 8 Two other common platelet
glycoprotein dimorphisms, glycoprotein IIb
Ile/Ser843 and glycoprotein Ia
Glu/Lys505, were not associated with
ischemic stroke in a single study,7 but the
Ile843 variant of glycoprotein IIb
was recently associated with increased mortality following
ischemic stroke in an elderly patient population.9
A nucleotide 807T variant of glycoprotein Ia
that correlates with increased platelet surface levels of
glycoprotein Ia/IIa (the platelet collagen
receptor)10 was recently associated with an increased risk
of ischemic stroke with onset at a young
age.11
|
The inconsistent results of studies examining the risk of stroke associated with genetic platelet glycoprotein variants may be partly due to differences in demographic characteristics between study populations. For example, genetic prothrombotic factors may be more important in younger individuals or premenopausal women12 13 who are less likely to have advanced atherosclerotic disease. Furthermore, the effect of single genetic factors on the risk of stroke may be weak when analyzed individually but may be more pronounced in the presence of other common genetic or environmental cardiovascular risk factors (eg, hypertension, smoking, obesity). We therefore assessed the association of 5 common platelet glycoprotein polymorphisms with stroke in young women (aged <45 years) and examined potential interactions between these genetic variants and other traditional cardiovascular risk factors.
| Subjects and Methods |
|---|
|
|
|---|
One hundred forty-nine of 198 eligible patients with nonfatal stroke
and 525 of 684 eligible control subjects were willing to participate in
an in-person interview. The interview involved ascertainment of
demographic characteristics and histories of traditional
cardiovascular risk factors, including hypertension,
diabetes, cigarette smoking,
hypercholesterolemia, height, weight,
contraceptive practices, menstrual status, and frequency of vigorous
exercise. All interview questions elicited information about the time
period before each subjects reference date, which was the date of
stroke for cases and a date assigned at random from among the potential
stroke occurrence dates for controls. A woman was classified as
hypertensive, diabetic, or hypercholesterolemic if she
reported ever receiving the diagnosis by a physician. Smokers were
defined as subjects who reported smoking both currently (within a month
of the reference date) and regularly (
5 cigarettes per week for
6
consecutive months). Obesity was defined as a body mass index
27.3
kg/m2. Physical inactivity was defined as
exercising vigorously <1 time per week. Hyperhomocysteinemia was
defined as a serum homocysteine level >12.6 µmol/L.
At the time of interview, venous blood samples were collected into
EDTA-treated evacuated tubes from 106 participating stroke cases (54
hemorrhagic, 41 ischemic, 2 venous, and 9 "other") and from
391 participating control subjects. Plasma and genomic DNA samples were
prepared as described previously.14 15 Genotyping for 5
platelet glycoprotein polymorphisms
(glycoprotein IIIa Leu/Pro33,
glycoprotein IIb Ile/Ser843,
glycoprotein Ib
Thr/Met145,
glycoprotein Ia Glu/Lys505, and
glycoprotein Ia C807T) was performed by polymerase chain
reaction amplification of genomic DNA followed by restriction enzyme
digestion (polymerase chain reactionrestriction fragment length
polymorphism), according to previously published
methods.16 17 18
In a previous analysis of the overall study sample, we determined that there was a significantly greater proportion of black women among the hemorrhagic stroke cases (11.8%) and ischemic stroke cases (11.7%) than among the control subjects (2.5%).14 Since the distribution of platelet glycoprotein alleles differs according to race, white and black subjects must be analyzed separately. However, because of the inadequate number of black women in the control group, we restricted the comparison of platelet glycoprotein genotypes to the subset of study subjects with DNA samples who were white (36 ischemic stroke cases, 42 hemorrhagic stroke cases, and 346 controls).
Platelet glycoprotein allele frequencies were calculated by gene counting. The association of platelet glycoprotein genotypes with stroke was examined by unconditional logistic regression adjusted for age and was expressed as odds ratios (ORs) and 95% CIs. Unless otherwise noted, ORs for the 5 biallelic platelet glycoprotein polymorphisms were calculated comparing individuals who were either heterozygous or homozygous for the less common allele with individuals who were homozygous for the more common allele. We also assessed the extent to which associations with platelet glycoprotein polymorphisms were modified by other cardiovascular risk factors, including smoking, obesity, hypertension, diabetes, and hyperhomocysteinemia, through analyses stratified on these cardiovascular risk factors.
| Results |
|---|
|
|
|---|
|
The genotype distributions of the 5 platelet
glycoprotein polymorphisms among the ischemic
stroke cases and control subjects are compared in Table 3
. A trend toward an association with
risk of ischemic stroke was observed for the
glycoprotein Ia C807T, glycoprotein
Ib
Thr/Met145, and
glycoprotein IIb Ile/Ser843
polymorphisms, but none of these reached the level of statistical
significance in the overall study sample. The age-adjusted OR for women
carrying
1 copy of the 807T allele was 2.24, and the lower
confidence limit was just <1.0 (95% CI=0.99 to 5.06). When
analyzed by subgroups defined according to the presence or
absence of other cardiovascular risk factors, the risk
of ischemic stroke associated with the 807T allele was
highest in the subgroup of women (16 cases and 91 controls) who were
obese (OR=3.24; 95% CI=0.86 to 12.18) and in the subgroup of women (13
cases and 86 controls) who had elevated plasma homocysteine levels
(OR=4.03; 95% CI=0.83 to 19.67).
|
The presence of
1 copy of the Met145 allele
of glycoprotein Ib
was associated with a more modestly
increased risk of ischemic stroke (OR=1.48; 95% CI=0.64 to
3.41). The risk associated with the Met145
allele of glycoprotein Ib
was highest in the
subgroup of women (15 cases and 40 controls) who carried a diagnosis of
either hypertension or diabetes (OR=3.86; 95% CI=0.98 to 15.17). In
the overall study population, the increased risk associated with the
Met145 variant was primarily due to an
overrepresentation of the Met/Met145
genotype among the ischemic stroke cases (5.6%)
compared with the controls (0.6%). This results in a large point
estimate for the risk of ischemic stroke associated with
Met145 homozygosity (age-adjusted OR=10.63), but
the CI is extremely wide (95% CI=1.43 to 79.34) because of the
relatively low frequency of this genotype.
Homozygosity for the Ser843 allele of glycoprotein IIb was also more prevalent in ischemic stroke cases (22.2%) than controls (14.4%) (OR=1.69; 95% CI=0.73 to 3.92). The risk of ischemic stroke associated with carrying 2 copies of the Ser843 allele was particularly high in the subgroup of women with hypertension or diabetes (OR=4.51; 95% CI=1.01 to 20.13) and in the subgroup of women with elevated plasma homocysteine levels (OR=5.94; 95% CI=1.53 to 23.05). By contrast, the risk associated with homozygosity for the glycoprotein IIb Ser843 allele was not increased in women without hypertension or diabetes (OR=0.94; 95% CI=0.27 to 3.33) or in women with normal plasma homocysteine levels (OR=0.83; 95% CI=0.23 to 2.94).
The genotype distributions of the 5 platelet
glycoprotein polymorphisms in hemorrhagic stroke cases
and control subjects are compared in Table 4
. The genotype distributions
were similar between hemorrhagic stroke cases and controls, either
overall or in the presence or absence of other
cardiovascular risk factors (data not shown).
|
| Discussion |
|---|
|
|
|---|
Thr/Met145,
and risk of ischemic stroke in young women. Although the
observed associations were modest, and the study was limited by small
numbers of stroke cases, 2 features of the study suggest that these
preliminary results may represent authentic associations.
First, there was evidence that the risk of ischemic stroke
associated with these genetic platelet glycoprotein
variants was highest in subgroups of women with other known
cardiovascular risk factors. These results are
consistent with previous studies that indicate the importance
of genetic prothrombotic factors in combination with other
cardiovascular risk factors in the occurrence of
atherothrombotic diseases such as myocardial infarction in young
adults.19 20 21 Second, we did not observe an association
between any of the platelet glycoprotein
polymorphisms and risk of hemorrhagic stroke, a disorder that does
not involve platelet-dependent thromboembolism.
Glycoprotein Ia/IIa is the major platelet collagen
receptor and is responsible for platelet adherence to exposed
vascular subendothelium. The 807T allele of
glycoprotein Ia was recently associated with a
statistically significant 3-fold increased risk of stroke in men and
women aged <50 years but was not associated with stroke in patients
aged >50 years.11 Our results in young women indicate an
2-fold increased risk of ischemic stroke associated with the
807T variant that was highest in women who were either obese or had
elevated plasma homocysteine levels. An increased risk of myocardial
infarction associated with the glycoprotein Ia 807T
allele similarly has been reported in young obese
men.22
The platelet glycoprotein Ib/IX complex is the major
platelet receptor for von Willebrand factor and is
responsible for initial platelet adhesion and activation following
exposure to vascular subendothelium under high shear
rates. Gonzalez-Conejero et al4 and Sonoda et
al5 each reported a 2- to 3-fold increased risk of
ischemic stroke or transient ischemic attack in men and
women who possessed
1 copy of the Met145
allele. Our results indicate a trend toward an increased risk of
ischemic stroke associated with the presence of
1 copy of the
Met145 allele in young women, particularly in
the subgroup of women who were hypertensive or diabetic. Moreover,
women who possessed 2 copies of the glycoprotein Ib
Met145 allele had an
10-fold increased
risk of ischemic stroke, although this estimate of effect was
statistically unstable because of the small sample size and relatively
low frequency of the Met145 variant.
The bridging of adjacent platelets through the glycoprotein IIb/IIIa receptor is important for thrombus formation, and glycoprotein IIb/IIIa inhibitors are used increasingly in the treatment of atherothrombotic disease. Carter et al2 reported an association between the Pro33 variant of platelet glycoprotein IIIa and risk of atherothrombotic stroke only in the subgroup of patients aged <50 years. Wagner et al3 reported a trend toward an association between the Pro33 variant of platelet glycoprotein IIIa and cerebral infarction in women aged <45 years when the analysis was restricted to whites. In contrast, we found no association between the glycoprotein IIIa Pro33 variant and risk of ischemic stroke in our population of young white women. Our negative findings are consistent with the results of 2 other case-control studies,6 7 as well as a prospective study of male physicians.8
The platelet glycoprotein IIb/IIIa receptor contains another prevalent polymorphism, glycoprotein IIb Ile/Ser843. Two studies have not observed an association between the Ile/Ser843 polymorphism of glycoprotein IIb and risk of cerebrovascular disease in older patient populations.7 9 Our results suggest a trend toward an association with increased risk of ischemic stroke in young women who are homozygous for the Ser843 variant. The risk associated with the glycoprotein IIb Ser/Ser843 genotype was most pronounced in women with hypertension or diabetes (OR=4.51; 95% CI=1.01 to 20.13) and in women with elevated plasma homocysteine levels (OR=5.94; 95% CI=1.53 to 23.05). Although the CIs were wide around these point estimates, they did not overlap 1.0. A recent preliminary report indicated that platelets containing the glycoprotein IIb Ser843 allele demonstrate increased in vitro platelet aggregation and clot retraction compared with those lacking the Ser843 allele23 and thus provides a possible explanation for the association between the Ser843 variant and risk of atherothrombotic disease.
Our findings are in contrast with another recent study that noted an association between the more common Ile843 variant of glycoprotein IIb and increased risk of poststroke mortality in an older patient population.9 Since our study analyzed only women who survived their acute event, it is possible that the women who died acutely had an overrepresentation of the Ile843 variant. Given the possible increased in vitro thrombogenicity of the Ser843 variant,23 one may speculate that the less adhesive Ile843 allele is associated with a increased tendency toward embolization of a preexisting platelet thrombus; this might account for increased mortality following the acute atherothrombotic event.9
Several limitations of our study should be noted. First, the relatively small number of cases and the performance of multiple subgroup analyses may increase the likelihood of a spurious association (type I statistical error). In this regard, some polymorphisms that have been associated with stroke or myocardial infarction in smaller studies have not been verified in larger, prospective studies.1 8 Second, the small number of cases decreases the likelihood of detecting weak associations (type II error). Third, blood samples for DNA analysis were collected at the time of subject interview; thus, as noted above, our study includes only women who survived an acute stroke. Therefore, if a particular platelet glycoprotein allele was associated with increased morbidity or early mortality, the effect could be underestimated because of exclusion of women who died acutely or were severely disabled. Fourth, our results apply to white, premenopausal women with acute stroke and may not be generalized to other demographic and ethnic groups. Thus, confirmation of the role of genetic platelet glycoprotein variants as risk factors for early-onset ischemic stroke requires further study involving larger numbers of subjects and other populations.
| Acknowledgments |
|---|
Received February 21, 2000; revision received April 18, 2000; accepted April 18, 2000.
| References |
|---|
|
|
|---|
2.
Carter AM, Catto AJ, Bamford JM, Grant PJ.
Platelet GP IIIa PlA and GP Ib variable
number tandem repeat polymorphisms and markers of platelet
activation in acute stroke. Arterioscler Thromb Vasc Biol. 1998;18:11241131.
3.
Wagner KR, Giles WH, Johnson CJ, Ou C-Y, Bray PF,
Goldschmidt-Clermont PJ, Croft JB, Brown VK, Stern BJ, Feeser BR,
Buchholz DW, Earley CJ, Macko RF, McCarter RJ, Sloan MA, Stolley PD,
Wityk RJ, Wozniak MA, Price TR, Kittner SJ. Platelet
glycoprotein receptor IIIa polymorphism PlA2 and
ischemic stroke risk. Stroke. 1998;29:581585.
4.
Gonzalez-Conejero R, Lozano ML, Rivera J, Corral J,
Iniesta JA, Moraleda JM, Vicente V. Polymorphisms of platelet
membrane glycoprotein Ib
associated with
arterial thrombotic disease. Blood. 1998;92:27712776.
5.
Sonoda A, Murata M, Ito D, Tanahashi N, Ohta A, Tada
Y, Takeshita E, Yoshida T, Saito I, Yamamoto M, Ikeda Y, Fukuuchi Y,
Watanabe K. Association between platelet glycoprotein
Ib
genotype and ischemic cerebrovascular
disease. Stroke.. 2000;31:493497.
6. Corral J, Gonzalez-Conejero R, Rivera J, Iniesta JA, Lozano ML, Vicente V. HPA-1 genotype in arterial thrombosis: role of HPA-1b polymorphism in platelet function. Blood Coag Fibrinol. 1997;8:284290.[Medline] [Order article via Infotrieve]
7.
Carlsson LE, Greinacher A, Spitzer C, Walther R,
Kessler C. Polymorphisms of the human platelet antigens HPA-1,
HPA-2, HPA-3, and HPA-5 on the platelet receptors for fibrinogen
(GPIIb/IIIa), von Willebrand factor (GPIb/IX), and collagen
(GPIa/IIa) are not correlated with an increased risk for stroke.
Stroke. 1997;28:13921395.
8. Ridker PM, Hennekens CH, Schmitz C, Stampfer MJ, Lindpaintner K. PlA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. Lancet. 1997;349:385388.[Medline] [Order article via Infotrieve]
9.
Carter AM, Catto AJ, Bamford JM, Grant PJ. Association
of the platelet glycoprotein IIb HPA-3 polymorphism
with survival after acute ischemic stroke. Stroke. 1999;30:26062611.
10.
Kunicki TJ, Kritzik M, Annis DS, Nugent DJ.
Hereditary variation in platelet integrin
2ß1 density is
associated with two silent polymorphisms in the
2 gene coding sequence. Blood. 1997;89:19391943.
11.
Carlsson LE, Santoso S, Spitzer C, Kessler C,
Greinacher A. The
2 gene coding sequence T807/A873 of the
platelet collagen receptor integrin
2ß1 might be a genetic
risk factor for the development of stroke in younger patients.
Blood. 1999;93:35833586.
12.
Margaglione M, DAndera G, Giuliani N, Brancaccio V,
De Lucia D, Grandone E, De Stefano V, Tonali PA, Di Minno G. Inherited
prothrombotic conditions and premature ischemic stroke: sex
difference in the association with factor V Leiden. Arterioscler
Thromb Vasc Biol. 1999;19:17511756.
13. Mohanty S, Saxena R, Behari M. Risk factors for thrombosis in nonembolic cerebrovascular disease. Am J Hematol. 1999;60:239241.[Medline] [Order article via Infotrieve]
14. Schwartz SM, Siscovick DS, Longstreth WT, Psaty BM, Beverly K, Raghunathan TE, Lin D, Koepsell TD. Use of low-dose contraceptives and stroke in young women. Ann Intern Med. 1997;127:596603.
15.
Longstreth WT Jr, Rosendaal FR, Siscovick DS, Vos HL,
Schwartz SM, Psaty BM, Raghunathan TE, Koepsell TD, Reitsma PH. Risk of
stroke in young women and two prothrombotic mutations: factor V
Leiden and prothrombin gene variant (G20210A). Stroke. 1998;29:577580.
16. Unkelbach K, Kalb R, Santoso S, Kroll H, Mueller-Eckhardt C, Kiefel V. Genomic RFLP typing of human platelet alloantigens Zw(PlA), Ko, Bak and Br (HPA-1, 2, 3, 5). Br J Haematol. 1995;89:169176.[Medline] [Order article via Infotrieve]
17.
Ishida F, Furihata K, Ishida K, Yan J, Kitano K,
Kiyosawa K, Furuta S. The largest variant of platelet
glycoprotein Ib
has four tandem repeats of 13 amino
acids in the macroglycopeptide region and a genetic linkage with
methionine. Blood. 1995;86:13561360.
18.
Reiner AP, Aramaki KM, Teramura G, Gaur L.
Analysis of platelet glycoprotein Ia
(
2 integrin) allele frequencies in
three North American populations reveals genetic association between
nucleotide 807C/T and amino acid 505 Glu/Lys (HPA-5)
dimorphisms. Thromb Haemost. 1998;80:449456.[Medline]
[Order article via Infotrieve]
19.
Rosendaal FR, Siscovick DS, Schwartz SM, Beverly RK,
Psaty BM, Longstreth WT Jr, Raghunathan TE, Koepsell TD, Reitsma PH.
Factor V Leiden (resistance to activated protein C)
increases the risk of myocardial infarction in young women.
Blood. 1997;89:28172821.
20.
Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM,
Raghunathan TE, Vos HL. A common prothrombin variant (20210 G to A)
increases the risk of myocardial infarction in young women.
Blood. 1997;90:17471750.
21. Inbal A, Freimark D, Modan B, Chetrit A, Matetzky S, Rosenberg N, Dradik R, Baron Z, Seligsohn U. Synergistic effects of prothrombotic polymorphisms and atherogenic factors on the risk of myocardial infarction in young males. Blood. 1999;39:21862190.
22.
Santoso S, Kunicki TJ, Kroll H, Haberbosch W, Gardemann
A. Association of the platelet glycoprotein Ia
C807T gene polymorphism with nonfatal
myocardial infarction in younger patients. Blood. 1999;93:24492453.
23. Bray PF, Michelson AD, Furman MI, Salmon J, Bolton E, Afshar-Khargan V, Lopez J. Correlating genetic variations in adhesive receptors with platelet function. Blood. 1999;94:216a. Abstract.
This article has been cited by other articles:
![]() |
C. Kleinschnitz, S. F. De Meyer, T. Schwarz, M. Austinat, K. Vanhoorelbeke, B. Nieswandt, H. Deckmyn, and G. Stoll Deficiency of von Willebrand factor protects mice from ischemic stroke Blood, April 9, 2009; 113(15): 3600 - 3603. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. C. Herak, M. R. Antolic, J. L. Krleza, M. Pavic, S. Dodig, V. Duranovic, A. B. Brkic, and R. Zadro Inherited Prothrombotic Risk Factors in Children With Stroke, Transient Ischemic Attack, or Migraine Pediatrics, April 1, 2009; 123(4): e653 - e660. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Maguire, A. Thakkinstian, J. Sturm, C. Levi, L. Lincz, M. Parsons, S. Whyte, and J. Attia Polymorphisms in Platelet Glycoprotein 1b{alpha} and Factor VII and Risk of Ischemic Stroke: A Meta-Analysis Stroke, June 1, 2008; 39(6): 1710 - 1716. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Kleinschnitz, M. Pozgajova, M. Pham, M. Bendszus, B. Nieswandt, and G. Stoll Targeting Platelets in Acute Experimental Stroke: Impact of Glycoprotein Ib, VI, and IIb/IIIa Blockade on Infarct Size, Functional Outcome, and Intracranial Bleeding Circulation, May 1, 2007; 115(17): 2323 - 2330. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Ostojic, D. Zelenika, R.B. Zotz, C. Sucker, Z. Ostojic, and R. Loncar Platelet Receptor HPA-1 Polymorphism of {alpha}IIb{beta}3 and 807 C/T Polymorphism of {alpha}2{beta}1 and Buerger's Disease Angiology, April 1, 2007; 58(2): 169 - 174. [Abstract] [PDF] |
||||
![]() |
J. P. Casas, A. D. Hingorani, L. E. Bautista, and P. Sharma Meta-analysis of Genetic Studies in Ischemic Stroke: Thirty-two Genes Involving Approximately 18 000 Cases and 58 000 Controls Arch Neurol, November 1, 2004; 61(11): 1652 - 1661. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Kunicki, A. B. Federici, D. R. Salomon, J. A. Koziol, S. R. Head, T. S. Mondala, J. D. Chismar, L. Baronciani, M. T. Canciani, and I. R. Peake An association of candidate gene haplotypes and bleeding severity in von Willebrand disease (VWD) type 1 pedigrees Blood, October 15, 2004; 104(8): 2359 - 2367. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Iniesta, R. Gonzalez-Conejero, C. Piqueras, V. Vicente, and J. Corral Platelet GP IIIa Polymorphism HPA-1 (PlA) Protects Against Subarachnoid Hemorrhage Stroke, October 1, 2004; 35(10): 2282 - 2286. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Slowik, T. Dziedzic, W. Turaj, J. Pera, L. Glodzik-Sobanska, P. Szermer, M. T. Malecki, D. A. Figlewicz, and A. Szczudlik A2 Alelle of GpIIIa Gene Is a Risk Factor for Stroke Caused by Large-Vessel Disease in Males Stroke, July 1, 2004; 35(7): 1589 - 1593. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. F. Meschia Addressing the Heterogeneity of the Ischemic Stroke Phenotype in Human Genetics Research Stroke, December 1, 2002; 33(12): 2770 - 2774. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Kittner Stroke in the young: Coming of age Neurology, July 9, 2002; 59(1): 6 - 7. [Full Text] [PDF] |
||||
![]() |
S. Bak, D. Gaist, S. H. Sindrup, A. Skytthe, and K. Christensen Genetic Liability in Stroke: A Long-Term Follow-Up Study of Danish Twins Stroke, March 1, 2002; 33(3): 769 - 774. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Kunicki The Influence of Platelet Collagen Receptor Polymorphisms in Hemostasis and Thrombotic Disease Arterioscler Thromb Vasc Biol, January 1, 2002; 22(1): 14 - 20. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.Y. Streifler, N. Rosenberg, A. Chetrit, R. Eskaraev, B.A. Sela, R. Dardik, A. Zivelin, B. Ravid, J. Davidson, U. Seligsohn, et al. Cerebrovascular Events in Patients With Significant Stenosis of the Carotid Artery Are Associated With Hyperhomocysteinemia and Platelet Antigen-1 (Leu33Pro) Polymorphism Stroke, December 1, 2001; 32(12): 2753 - 2758. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. F. O'Connor, D. C. Shields, A. Fitzgerald, C. P. Cannon, E. Braunwald, and D. J. Fitzgerald Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes Blood, December 1, 2001; 98(12): 3256 - 3260. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Mikkelsson, M. Perola, A. Penttila, and P. J. Karhunen Platelet Glycoprotein Ib{alpha} HPA-2 Met/VNTR B Haplotype as a Genetic Predictor of Myocardial Infarction and Sudden Cardiac Death Circulation, August 21, 2001; 104(8): 876 - 880. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. B. Frank, A. P. Reiner, S. M. Schwartz, P. N. Kumar, R. M. Pearce, P. G. Arbogast, W. T. Longstreth Jr, F. R. Rosendaal, B. M. Psaty, and D. S. Siscovick The Kozak sequence polymorphism of platelet glycoprotein Ib{alpha} and risk of nonfatal myocardial infarction and nonfatal stroke in young women Blood, February 15, 2001; 97(4): 875 - 879. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |